The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).
Trial DetailsThe safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).
NCT Number NCT05312151
Sponsors & CollaboratorsCOMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.
King's College London
KCL is home to the Psychedleic Trials Group.
Measures UsedClinician-Administered PTSD Scale for DSM-5
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is often considered the gold standard in PTSD assessment. The 30-item structured interview was developed by staff at the U.S. Department of Veterans Affairs National Centre for PTSD. CAPS can be used to make a current diagnosis, lifetime diagnosis or assess PTSD symptoms over the past week in accordance with DSM-5 criteria.